471
On 17 April 2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 434. The active ingredient is pralatrexate for treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).